Key result
Aggressive LDL-C lowering (target 93-97 mg/dL) delayed progression of atherosclerosis in saphenous vein grafts across all subgroups, consistent with the 31% reduction seen in the main trial.
Why the study?
Does aggressive LDL-C lowering reduce the progression of saphenous vein graft atherosclerosis across different patient subgroups?
Population
Patients with saphenous vein grafts enrolled in the NHLBI Post Coronary Artery Bypass Graft trial
Comparison
Aggressive lowering of LDL-C using lovastatin… vs Moderate lowering of LDL-C
Design
RCT
Authors
Loading...
Supports aggressive LDL-C lowering post-CABG across patients; extends main trial efficacy to all subgroups.
RCT
Does aggressive LDL-C lowering reduce the progression of saphenous vein graft atherosclerosis across different patient subgroups?
Aggressive LDL-C lowering consistently delays the progression of saphenous vein graft atherosclerosis regardless of age, gender, or the presence of other coronary heart disease risk factors.
Campeau et al. (1999) conducted an RCT in Post Coronary Artery Bypass Graft (CABG) with saphenous vein grafts. Aggressive LDL-C lowering (lovastatin and cholestyramine) vs. Moderate LDL-C lowering (target 132-136 mg/dL) was evaluated on Progression of atherosclerosis (lumen diameter decrease ≥0.6 mm). Aggressive LDL-C lowering (target 93-97 mg/dL) delayed progression of atherosclerosis in saphenous vein grafts across all subgroups, consistent with the 31% reduction seen in the main trial.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: